1152475-62-1

Usage

Uses

Used in Medicinal Chemistry:
2-Chloro-7-iodo-5-methyl-5H-pyrrolo[3,2-d]pyrimidine is used as a chemical compound in medicinal chemistry for its potential to interact with biological targets. Its unique structure allows it to modulate cellular processes, making it a promising candidate for the development of novel therapies.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Chloro-7-iodo-5-methyl-5H-pyrrolo[3,2-d]pyrimidine is utilized as a key component in drug discovery and development. Its ability to modulate cellular processes and interact with biological targets positions it as a valuable asset in the search for new treatments for various diseases.
Further research and study may uncover additional uses and benefits of 2-Chloro-7-iodo-5-methyl-5H-pyrrolo[3,2-d]pyrimidine in the fields of chemical and pharmaceutical sciences, expanding its applications and potential impact on human health.

Upstream product

• 1152475-50-7 2-chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine 
• 74-88-4 methyl iodide 

Downstream Products

• 1152475-64-3 N-[3-(2-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl]methanesulfonamide 

Relevant academic research and scientific papers

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist

The nuclear hormone receptor retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) is a promising target for the treatment of autoimmune diseases. A small molecule, inverse agonist of the receptor is anticipated to reduce production of IL-17, a key proinflammatory cytokine. Through a high-throughput screening approach, we identified a molecule displaying promising binding affinity for RORC2, inhibition of IL-17 production in Th17 cells, and selectivity against the related RORA and RORB receptor isoforms. Lead optimization to improve the potency and metabolic stability of this hit focused on two key design strategies, namely, iterative optimization driven by increasing lipophilic efficiency and structure-guided conformational restriction to achieve optimal ground state energetics and maximize receptor residence time. This approach successfully identified 3-cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide as a potent and selective RORC2 inverse agonist, demonstrating good metabolic stability, oral bioavailability, and the ability to reduce IL-17 levels and skin inflammation in a preclinical in vivo animal model upon oral administration.

RORC2 INHIBITORS AND METHODS OF USE THEREOF

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

N-CONTAINING HETEROCYCLIC COMPOUNDS

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.